It’s been a crucial week for XOMA Corporation (NASDAQ:XOMA); here’s what analysts have to say.

July 16, 2018 - By Richard Slagle

XOMA Corporation (NASDAQ:XOMA) Logo

XOMA Corporation (NASDAQ:XOMA) Ratings Coverage

Among 2 analysts covering Xoma Corp (NASDAQ:XOMA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Xoma Corp had 5 analyst reports since January 18, 2018 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Monday, April 30. Wedbush maintained XOMA Corporation (NASDAQ:XOMA) rating on Tuesday, February 6. Wedbush has “Buy” rating and $33.0 target. The rating was maintained by H.C. Wainwright on Thursday, January 18 with “Buy”. H.C. Wainwright maintained the shares of XOMA in report on Friday, March 9 with “Buy” rating. Wedbush maintained XOMA Corporation (NASDAQ:XOMA) rating on Monday, May 21. Wedbush has “Buy” rating and $3300 target. Below is a list of XOMA Corporation (NASDAQ:XOMA) latest ratings and price target changes.

21/05/2018 Broker: Wedbush Rating: Buy New Target: $33.0000 Maintain
30/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $49.0000 Maintain
09/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $49.0 Maintain
06/02/2018 Broker: Wedbush Rating: Buy New Target: $33.0 Maintain
18/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $49.0 Maintain

The stock decreased 1.56% or $0.36 during the last trading session, reaching $22.75. About 26,940 shares traded. XOMA Corporation (NASDAQ:XOMA) has risen 273.57% since July 16, 2017 and is uptrending. It has outperformed by 261.00% the S&P500.

XOMA Corporation discovers, develops, and commercializes antibody therapeutics in the United States, Europe, and the Asia Pacific. The company has market cap of $190.63 million. The companyÂ’s product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. It has a 10.35 P/E ratio. The Company’s preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy.

Another recent and important XOMA Corporation (NASDAQ:XOMA) news was published by Nasdaq.com which published an article titled: “XOMA Added to the Russell 2000® and Russell 3000® Indexes” on June 26, 2018.

XOMA Corporation (NASDAQ:XOMA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.